The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

New ISO standards categorize SVIOLs into multifocal, EDOF, and FVR IOLs, requiring rigorous clinical testing for ...

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.